Last updated on October 2020

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Brief description of study

The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in participants with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrm macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma intolerant of prior ibrutinib and/or acalabrutinib treatment, compared with their ibrutinib and/or acalabrutinib intolerance adverse event profile as assessed by the recurrence and the change in severity of adverse events.

Clinical Study Identifier: NCT04116437

Find a site near you

Start Over

Tennessee Oncology

Nashville, TN United States
  Connect »

Medical Oncology Associates

Spokane, WA United States
  Connect »

Texas Oncology-Amarillo

Amarillo, TX United States
  Connect »

Texas Oncology-Arlington South

Arlington, TX United States
  Connect »

Morristown Medical Center

Morristown, NJ United States
  Connect »

Healthcare Research Network

Tinley Park, IL United States
  Connect »

CCI Clearview Cancer Insitute

Huntsville, AL United States
  Connect »

Texas Oncology

Austin, TX United States
  Connect »

Virginia Cancer Specialists

Gainesville, VA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.